Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,658,383 papers from all fields of science
Search
Sign In
Create Free Account
Stage III Lung Adenocarcinoma
Known as:
Stage III Adenocarcinoma of Lung
, Stage III Lung Adenocarcinoma AJCC v7
, Stage III Adenocarcinoma of the Lung
Expand
Stage III includes: IIIA (T1a, N2, M0); (T1b, N2, M0); (T2a, N2, M0); (T2b, N2, M0); (T3, N1, M0); (T3, N2, M0); (T4, N0, M0); (T4, N1, M0) and IIIB…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
27 relations
ALK gene
Chest
Chromosome 13q deletion
Coughing
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Use of 18F-FDG PET/CT to predict short-term outcomes early in the course of chemoradiotherapy in stage III adenocarcinoma of the lung.
Xiang-Rong Zhao
,
Yong Zhang
,
Yong-hua Yu
Oncology letters
2018
Corpus ID: 51876668
The purpose of the present prospective study was to evaluate the use of 18F-fluorodeoxyglucose positron emission tomography…
Expand
2017
2017
Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?
Tian Zhang
,
Jing Wang
,
+8 authors
Ping Wang
Oncotarget
2017
Corpus ID: 4756666
Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein encoded by a gene located in the short arm of chromosome…
Expand
2016
2016
Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001)
W. Ou
,
Ning Li
,
+4 authors
Bao-Xiao Wang
Cancer
2016
Corpus ID: 38684556
The objective of this phase 2 trial was to assess the efficacy and safety of induction bevacizumab plus chemotherapy followed by…
Expand
2016
2016
A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma
Yiyu Lu
,
W. Gu
,
Jin Deng
,
Hua Yang
,
Wen Yang
BMC Cancer
2016
Corpus ID: 17321553
BackgroundConcurrent chemotherapy and radiation is the standard treatment for unresectable stage III Lung adenocarcinoma. However…
Expand
2016
2016
Whole exome sequencing analysis of the neoadjuvant bevacizumab plus pemetrexed and carboplatin for unresectable stage III lung adenocarcinoma: Results of the phase II GASTO 1001 trial.
Si Yu Wang
,
W. Ou
,
Ning Li
,
Pengfei Xu
,
Xiaoyong Mao
,
Bao-Xiao Wang
2016
Corpus ID: 80706926
e20045Background: GASTO 1001 is a phase II trial investigating the efficacy and safety of induction bevacizumab plus chemotherapy…
Expand
2015
2015
Phase II trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001).
Si Yu Wang
,
W. Ou
,
+5 authors
Bao-Xiao Wang
2015
Corpus ID: 196485888
7528 Background: Unresectable stage III non-small cell lung cancer is often treated with concurrent chemoradiotherapy…
Expand
2014
2014
The impact of EGFR mutation on definitive concurrent chemoradiation therapy for inoperable stage III lung adenocarcinoma.
Kosuke Tanaka
,
T. Oguri
,
+5 authors
T. Hida
2014
Corpus ID: 78257224
7558 Background: Concurrent chemoradiation therapy (CRT) is the current standard of care for patients with locally advanced lung…
Expand
2012
2012
Recruitment of Podoplanin Positive Cancer-Associated Fibroblasts in Metastatic Lymph Nodes Predicts Poor Prognosis in Pathological N2 Stage III Lung Adenocarcinoma
S. Neri
,
G. Ishii
,
+5 authors
A. Ochiai
Annals of Surgical Oncology
2012
Corpus ID: 23666794
BackgroundCancer-associated fibroblasts (CAFs) directly communicate with cancer cells and play important roles in cancer…
Expand
Review
2012
Review
2012
Brain metastases after definitive concurrent chemoradiotherapy in patients with stage III lung adenocarcinoma: Carcinoembryonic antigen as a potential predictive factor
H. Horinouchi
,
I. Sekine
,
+5 authors
T. Tamura
Cancer science
2012
Corpus ID: 205237686
The predictive factors for the development of brain metastases in patients with stage III non‐small‐cell lung cancer receiving…
Expand
1988
1988
Prediction of the clinical chemotherapeutic response of stage III lung adenocarcinoma patients by an in vitro short term test.
M. Volm
,
P. Drings
,
E. W. Hahn
,
J. Mattern
British Journal of Cancer
1988
Corpus ID: 3064099
Prediction of the clinical chemotherapeutic response of stage III lung adenocarcinoma patients by an in vitro short term test
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE